Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies
While cytokine release syndrome and neurotoxicity are widely reported as the most common acute CAR T-cell toxicities, it is essential for providers to understand that CAR T-cell therapy may also result in other toxicities (such as infections, cytopenias, or B-cell aplasia), some of which could persist for months to years after infusion.
Category
- Management of Immunotherapy-Related Toxicities
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers
Bispecific T-cell engagers are emerging as promising treatment options for patients with heavily pretreated multiple myeloma and B-cell lymphomas, especially for patients with disease relapse following CAR T-cell therapy. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit associated with bispecific T-cell engager therapy.
Category
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Navigating Change: Best Practices for Integrating WHO/ICC Classification Systems in the Management of Hematologic Malignancies
A better understanding of the pathogenesis of hematologic malignancies has led to the identification of new cytogenetic and molecular markers that distinguish between the various subtypes of hematologic malignancies. Informing hematologists and oncologists about the updated WHO5 classification and the new ICC will aid in the accurate diagnosis and development of a treatment plan to the specific subtype of hematologic malignancy.
Category
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Updates in the Management of Mantle Cell Lymphoma: Is There Still a Role for Transplant?
Recent advances in mantle cell lymphoma represent a major paradigm shift. Educating the clinicians about the recent advances and the benefits/risks associated with the use of hematopoietic cell transplant, BTK inhibitors (BTKi) and CAR T-cell therapy can help them make informed clinical decisions for individual patients.
Category
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Management of Toxicities of BTK Inhibitors in B-Cell Malignancies
Bruton’s tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape of B-cell malignancies. A thorough understanding of the mechanism of action (covalent vs. non-covalent), similarities and differences in their safety profile and management of specific treatment-related adverse events will enable clinicians to use these agents safely and effectively in routine clinical practice.
Category
- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Current Treatment Approaches for Transformed Indolent B-Cell Lymphomas
Education about the recent advances and special considerations associated with the diagnosis and management of transformed indolent lymphomas is essential to facilitate the incorporation of novel treatment options into routine clinical practice to improve clinical outcomes.
Category
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 0.75 ANCC contact hours
- 0.75 Participation